Published in Proc Natl Acad Sci U S A on November 11, 1997
Aggresomes: a cellular response to misfolded proteins. J Cell Biol (1998) 11.24
Recognition and processing of ubiquitin-protein conjugates by the proteasome. Annu Rev Biochem (2009) 8.83
The ubiquitin-proteasome pathway: on protein death and cell life. EMBO J (1998) 6.37
Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer. Blood (2007) 3.94
Cytotoxic T lymphocyte therapy for Epstein-Barr virus+ Hodgkin's disease. J Exp Med (2004) 3.57
Functions of NF-kappaB1 and NF-kappaB2 in immune cell biology. Biochem J (2004) 3.01
Structural insights into the regulatory particle of the proteasome from Methanocaldococcus jannaschii. Mol Cell (2009) 2.75
Human CD4(+) T lymphocytes consistently respond to the latent Epstein-Barr virus nuclear antigen EBNA1. J Exp Med (2000) 2.48
Maintenance of Epstein-Barr virus (EBV) oriP-based episomes requires EBV-encoded nuclear antigen-1 chromosome-binding domains, which can be replaced by high-mobility group-I or histone H1. Proc Natl Acad Sci U S A (2001) 2.26
Comparative immune response to PE and PE_PGRS antigens of Mycobacterium tuberculosis. Infect Immun (2001) 2.26
Aggresomes and Russell bodies. Symptoms of cellular indigestion? EMBO Rep (2000) 2.01
Laboratory assays for Epstein-Barr virus-related disease. J Mol Diagn (2008) 1.82
DNA and RNA-based vaccines: principles, progress and prospects. Vaccine (1999) 1.76
Lymphomas differ in their dependence on Epstein-Barr virus. Blood (2010) 1.74
Evidence for the presentation of major histocompatibility complex class I-restricted Epstein-Barr virus nuclear antigen 1 peptides to CD8+ T lymphocytes. J Exp Med (2004) 1.72
The plasmid replicon of Epstein-Barr virus: mechanistic insights into efficient, licensed, extrachromosomal replication in human cells. Plasmid (2007) 1.72
Genetic evidence that EBNA-1 is needed for efficient, stable latent infection by Epstein-Barr virus. J Virol (1999) 1.70
Immunity and immunopathology to viruses: what decides the outcome? Nat Rev Immunol (2010) 1.69
Sequential assistance of molecular chaperones and transient formation of covalent complexes during protein degradation from the ER. J Cell Biol (2002) 1.68
EBNA1-specific CD4+ T cells in healthy carriers of Epstein-Barr virus are primarily Th1 in function. J Clin Invest (2001) 1.53
C9orf72 FTLD/ALS-associated Gly-Ala dipeptide repeat proteins cause neuronal toxicity and Unc119 sequestration. Acta Neuropathol (2014) 1.48
CD8 T cell recognition of endogenously expressed epstein-barr virus nuclear antigen 1. J Exp Med (2004) 1.47
Endogenous presentation of CD8+ T cell epitopes from Epstein-Barr virus-encoded nuclear antigen 1. J Exp Med (2004) 1.45
Differences in gastric carcinoma microenvironment stratify according to EBV infection intensity: implications for possible immune adjuvant therapy. PLoS Pathog (2013) 1.43
Gammaherpesvirus and lymphoproliferative disorders in immunocompromised patients. Cancer Lett (2011) 1.41
Epstein-Barr virus gp42 is posttranslationally modified to produce soluble gp42 that mediates HLA class II immune evasion. J Virol (2005) 1.36
Varicella-zoster virus retains major histocompatibility complex class I proteins in the Golgi compartment of infected cells. J Virol (2001) 1.36
Cytolytic CD4(+)-T-cell clones reactive to EBNA1 inhibit Epstein-Barr virus-induced B-cell proliferation. J Virol (2003) 1.36
The role of the proteasome in the generation of MHC class I ligands and immune responses. Cell Mol Life Sci (2011) 1.35
Glycine-alanine repeats impair proper substrate unfolding by the proteasome. EMBO J (2006) 1.34
Stepwise unfolding of a β barrel protein by the AAA+ ClpXP protease. J Mol Biol (2011) 1.33
Dendritic cells initiate immune control of epstein-barr virus transformation of B lymphocytes in vitro. J Exp Med (2003) 1.31
Regulation of protein translation through mRNA structure influences MHC class I loading and T cell recognition. Proc Natl Acad Sci U S A (2008) 1.28
Inhibition of antigen presentation by the glycine/alanine repeat domain is not conserved in simian homologues of Epstein-Barr virus nuclear antigen 1. J Virol (1999) 1.28
The Epstein-Barr virus latency BamHI-Q promoter is positively regulated by STATs and Zta interference with JAK/STAT activation leads to loss of BamHI-Q promoter activity. Proc Natl Acad Sci U S A (1999) 1.27
Epstein-Barr virus BARF1 protein is dispensable for B-cell transformation and inhibits alpha interferon secretion from mononuclear cells. J Virol (1999) 1.27
Epstein-Barr virus infection and human malignancies. Int J Exp Pathol (2001) 1.24
Expression of EBNA-1 mRNA is regulated by cell cycle during Epstein-Barr virus type I latency. J Virol (1999) 1.23
Structural motifs involved in ubiquitin-mediated processing of the NF-kappaB precursor p105: roles of the glycine-rich region and a downstream ubiquitination domain. Mol Cell Biol (1999) 1.22
Protein array identification of substrates of the Epstein-Barr virus protein kinase BGLF4. J Virol (2009) 1.21
Autophagy in the regulation of pathogen replication and adaptive immunity. Trends Immunol (2012) 1.21
Influence of translation efficiency of homologous viral proteins on the endogenous presentation of CD8+ T cell epitopes. J Exp Med (2007) 1.16
Variation of the Mycobacterium tuberculosis PE_PGRS 33 gene among clinical isolates. J Clin Microbiol (2005) 1.15
A genome-wide integrative genomic study localizes genetic factors influencing antibodies against Epstein-Barr virus nuclear antigen 1 (EBNA-1). PLoS Genet (2013) 1.15
The expression and function of Epstein-Barr virus encoded latent genes. Mol Pathol (2000) 1.12
Epstein-barr virus: environmental trigger of multiple sclerosis? J Virol (2007) 1.11
Yeast SREBP cleavage activation requires the Golgi Dsc E3 ligase complex. Mol Cell (2011) 1.11
Translating DRiPs: progress in understanding viral and cellular sources of MHC class I peptide ligands. Cell Mol Life Sci (2011) 1.11
Epstein-barr virus nuclear antigen 1: from immunologically invisible to a promising T cell target. J Exp Med (2004) 1.09
Gly-Ala repeats induce position- and substrate-specific regulation of 26 S proteasome-dependent partial processing. J Biol Chem (2008) 1.08
Functional macroautophagy induction by influenza A virus without a contribution to major histocompatibility complex class II-restricted presentation. J Virol (2011) 1.07
Hsp90 inhibitors block outgrowth of EBV-infected malignant cells in vitro and in vivo through an EBNA1-dependent mechanism. Proc Natl Acad Sci U S A (2010) 1.07
Slippery substrates impair ATP-dependent protease function by slowing unfolding. J Biol Chem (2013) 1.06
Physical association of the K3 protein of gamma-2 herpesvirus 68 with major histocompatibility complex class I molecules with impaired peptide and beta(2)-microglobulin assembly. J Virol (2002) 1.05
The synthesis of truncated polypeptides for immune surveillance and viral evasion. PLoS One (2010) 1.04
Non-conventional sources of peptides presented by MHC class I. Cell Mol Life Sci (2011) 1.03
Epstein-Barr virus and Burkitt lymphoma. Chin J Cancer (2014) 1.02
Immune escape by Epstein-Barr virus associated malignancies. Semin Cancer Biol (2008) 1.02
Suppression of Epstein-Barr nuclear antigen 1 (EBNA1) by RNA interference inhibits proliferation of EBV-positive Burkitt's lymphoma cells. J Cancer Res Clin Oncol (2005) 1.02
MYC overexpression imposes a nonimmunogenic phenotype on Epstein-Barr virus-infected B cells. Proc Natl Acad Sci U S A (2002) 1.01
Inhibition of proteasomal degradation by the gly-Ala repeat of Epstein-Barr virus is influenced by the length of the repeat and the strength of the degradation signal. Proc Natl Acad Sci U S A (2000) 1.00
Type 2 cytokines predominate in the human CD4(+) T-lymphocyte response to Epstein-Barr virus nuclear antigen 1. J Virol (2000) 0.98
Epstein-Barr virus nuclear antigen 1 does not induce lymphoma in transgenic FVB mice. Proc Natl Acad Sci U S A (2005) 0.97
Modulation of p53 activity by IkappaBalpha: evidence suggesting a common phylogeny between NF-kappaB and p53 transcription factors. BMC Immunol (2005) 0.97
Epstein-Barr virus latent genes. Exp Mol Med (2015) 0.96
An adenovirus-Epstein-Barr virus hybrid vector that stably transforms cultured cells with high efficiency. J Virol (1999) 0.96
The expression of genes coding for distinct types of glycine-rich proteins varies according to the biology of three metastriate ticks, Rhipicephalus (Boophilus) microplus, Rhipicephalus sanguineus and Amblyomma cajennense. BMC Genomics (2010) 0.95
Epstein-Barr virus and systemic lupus erythematosus. Clin Dev Immunol (2012) 0.95
The CD8+ T-cell response to an Epstein-Barr virus-related gammaherpesvirus infecting rhesus macaques provides evidence for immune evasion by the EBNA-1 homologue. J Virol (2005) 0.95
A novel HLA-A*0201 restricted peptide derived from cathepsin G is an effective immunotherapeutic target in acute myeloid leukemia. Clin Cancer Res (2012) 0.95
Autorepression of Epstein-Barr virus nuclear antigen 1 expression by inhibition of pre-mRNA processing. J Virol (2007) 0.95
Epstein-Barr virus in human malignancy: a special reference to Epstein-Barr virus associated gastric carcinoma. Cancer Res Treat (2005) 0.94
Immune responses to Epstein-Barr virus: molecular interactions in the virus evasion of CD8+ T cell immunity. Microbes Infect (2010) 0.94
T cell detection of a B-cell tropic virus infection: newly-synthesised versus mature viral proteins as antigen sources for CD4 and CD8 epitope display. PLoS Pathog (2009) 0.94
Reduced response to Epstein-Barr virus antigens by T-cells in systemic lupus erythematosus patients. Lupus Sci Med (2014) 0.93
Bioinformatic analysis of functional differences between the immunoproteasome and the constitutive proteasome. Immunogenetics (2003) 0.93
Therapeutic implications of Epstein-Barr virus infection for the treatment of nasopharyngeal carcinoma. Ther Clin Risk Manag (2014) 0.92
Functional p53 chimeras containing the Epstein-Barr virus Gly-Ala repeat are protected from Mdm2- and HPV-E6-induced proteolysis. Proc Natl Acad Sci U S A (2002) 0.91
Detailed analysis of Epstein-Barr virus-specific CD4+ and CD8+ T cell responses during infectious mononucleosis. Clin Exp Immunol (2008) 0.90
Accessing Epstein-Barr virus-specific T-cell memory with peptide-loaded dendritic cells. J Virol (1999) 0.89
Lessons from viral manipulation of protein disposal pathways. J Clin Invest (2002) 0.88
Viral evasion of the MHC class I antigen-processing machinery. Pflugers Arch (2005) 0.87
Disordered proteinaceous machines. Chem Rev (2014) 0.86
Phosphorylation sites of Epstein-Barr virus EBNA1 regulate its function. J Gen Virol (2009) 0.86
The Epstein-Barr Virus EBNA1 Protein. Scientifica (Cairo) (2012) 0.85
Proteasome inhibitors induce the presentation of an Epstein-Barr virus nuclear antigen 1-derived cytotoxic T lymphocyte epitope in Burkitt's lymphoma cells. Immunology (2011) 0.85
Finding a place for tumor-specific T cells in targeted cancer therapy. J Exp Med (2004) 0.85
Latent Membrane Protein LMP2A Impairs Recognition of EBV-Infected Cells by CD8+ T Cells. PLoS Pathog (2015) 0.84
Environmental stresses induce misfolded protein aggregation in plant cells in a microtubule-dependent manner. Int J Mol Sci (2013) 0.84
Immune escape of γ-herpesviruses from adaptive immunity. Rev Med Virol (2014) 0.84
Secreted antiviral entry inhibitory (SAVE) peptides for gene therapy of HIV infection. Mol Ther (2011) 0.83
Variations of Epstein-Barr virus nuclear antigen 1 in Epstein-Barr virus-associated gastric carcinomas from Guangzhou, southern China. PLoS One (2012) 0.83
Prospects of a novel vaccination strategy for human gamma-herpesviruses. Immunol Res (2010) 0.82
EBV Persistence-Introducing the Virus. Curr Top Microbiol Immunol (2015) 0.82
Autophagy and immunity - insights from human herpesviruses. Front Immunol (2012) 0.82
Adoptive T-Cell Immunotherapy. Curr Top Microbiol Immunol (2015) 0.81
The B subunit of Escherichia coli heat-labile enterotoxin enhances CD8+ cytotoxic-T-lymphocyte killing of Epstein-Barr virus-infected cell lines. J Virol (2003) 0.81
The epitopes of influenza nucleoprotein recognized by cytotoxic T lymphocytes can be defined with short synthetic peptides. Cell (1986) 14.96
Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules. Cell (1994) 11.73
The ubiquitin-proteasome proteolytic pathway. Cell (1994) 9.75
A multiubiquitin chain is confined to specific lysine in a targeted short-lived protein. Science (1989) 9.68
Components of ubiquitin-protein ligase system. Resolution, affinity purification, and role in protein breakdown. J Biol Chem (1983) 7.03
Ubiquitination of a yeast plasma membrane receptor signals its ligand-stimulated endocytosis. Cell (1996) 6.51
Ubiquitin, proteasomes, and the regulation of intracellular protein degradation. Curr Opin Cell Biol (1995) 5.74
Inhibition of antigen processing by the internal repeat region of the Epstein-Barr virus nuclear antigen-1. Nature (1995) 4.53
Identification of target antigens for the human cytotoxic T cell response to Epstein-Barr virus (EBV): implications for the immune control of EBV-positive malignancies. J Exp Med (1992) 4.11
Spontaneous assembly of a self-complementary oligopeptide to form a stable macroscopic membrane. Proc Natl Acad Sci U S A (1993) 4.05
Localization of Epstein-Barr virus cytotoxic T cell epitopes using recombinant vaccinia: implications for vaccine development. J Exp Med (1992) 3.75
Antigen processing and presentation by the class I major histocompatibility complex. Annu Rev Immunol (1996) 2.69
Predicted alpha-helical regions of the prion protein when synthesized as peptides form amyloid. Proc Natl Acad Sci U S A (1992) 2.64
Ubiquitin-aldehyde: a general inhibitor of ubiquitin-recycling processes. Proc Natl Acad Sci U S A (1987) 2.52
Surface hydrophobic residues of multiubiquitin chains essential for proteolytic targeting. Proc Natl Acad Sci U S A (1996) 2.50
Stress resistance in Saccharomyces cerevisiae is strongly correlated with assembly of a novel type of multiubiquitin chain. Mol Cell Biol (1994) 2.44
Antibodies against a synthetic peptide identify the Epstein-Barr virus-determined nuclear antigen. Proc Natl Acad Sci U S A (1984) 2.40
Resolution of the ATP-dependent proteolytic system from reticulocytes: a component that interacts with ATP. Proc Natl Acad Sci U S A (1979) 2.37
A role for the ubiquitin-dependent proteolytic pathway in MHC class I-restricted antigen presentation. Nature (1993) 2.11
Silk properties determined by gland-specific expression of a spider fibroin gene family. Science (1996) 2.01
A glycine-rich region in NF-kappaB p105 functions as a processing signal for the generation of the p50 subunit. Mol Cell Biol (1996) 2.01
Epstein-Barr virus: adaptation to a life within the immune system. Trends Microbiol (1994) 1.90
Epitope focusing in the primary cytotoxic T cell response to Epstein-Barr virus and its relationship to T cell memory. J Exp Med (1996) 1.85
Separation of the complex DNA binding domain of EBNA-1 into DNA recognition and dimerization subdomains of novel structure. J Virol (1993) 1.55
The proteasome-specific inhibitor lactacystin blocks presentation of cytotoxic T lymphocyte epitopes in human and murine cells. Eur J Immunol (1997) 1.51
Direct conversion of an oligopeptide from a beta-sheet to an alpha-helix: a model for amyloid formation. Proc Natl Acad Sci U S A (1997) 1.36
The role of repetitive DNA sequences in the size variation of Epstein-Barr virus (EBV) nuclear antigens, and the identification of different EBV isolates using RFLP and PCR analysis. J Gen Virol (1995) 1.16
The epstein-Barr-virus-encoded membrane protein LMP but not the nuclear antigen EBNA-1 induces rejection of transfected murine mammary carcinoma cells. Int J Cancer (1991) 1.01
The ubiquitin system. Annu Rev Biochem (1998) 43.36
The ubiquitin system for protein degradation. Annu Rev Biochem (1992) 8.84
pH and the recycling of transferrin during receptor-mediated endocytosis. Proc Natl Acad Sci U S A (1983) 8.41
Components of ubiquitin-protein ligase system. Resolution, affinity purification, and role in protein breakdown. J Biol Chem (1983) 7.03
Ubiquitin dependence of selective protein degradation demonstrated in the mammalian cell cycle mutant ts85. Cell (1984) 6.81
Ubiquitin ligase activity and tyrosine phosphorylation underlie suppression of growth factor signaling by c-Cbl/Sli-1. Mol Cell (1999) 6.79
Thermolability of ubiquitin-activating enzyme from the mammalian cell cycle mutant ts85. Cell (1984) 5.70
Short-lived green fluorescent proteins for quantifying ubiquitin/proteasome-dependent proteolysis in living cells. Nat Biotechnol (2000) 5.14
Mechanisms of intracellular protein breakdown. Annu Rev Biochem (1982) 4.89
Kinetics of internalization and recycling of transferrin and the transferrin receptor in a human hepatoma cell line. Effect of lysosomotropic agents. J Biol Chem (1983) 4.55
Inhibition of antigen processing by the internal repeat region of the Epstein-Barr virus nuclear antigen-1. Nature (1995) 4.53
Basic Medical Research Award. The ubiquitin system. Nat Med (2000) 4.03
Regulation of stability and function of the epithelial Na+ channel (ENaC) by ubiquitination. EMBO J (1997) 4.01
Proposed role of ATP in protein breakdown: conjugation of protein with multiple chains of the polypeptide of ATP-dependent proteolysis. Proc Natl Acad Sci U S A (1980) 3.75
Guidelines for the use and interpretation of assays for monitoring cell death in higher eukaryotes. Cell Death Differ (2009) 3.44
ATP-dependent conjugation of reticulocyte proteins with the polypeptide required for protein degradation. Proc Natl Acad Sci U S A (1980) 2.96
Functional interaction between SEL-10, an F-box protein, and the nuclear form of activated Notch1 receptor. J Biol Chem (2001) 2.71
The ubiquitin-proteasome pathway and pathogenesis of human diseases. Annu Rev Med (1999) 2.68
Stimulation-dependent I kappa B alpha phosphorylation marks the NF-kappa B inhibitor for degradation via the ubiquitin-proteasome pathway. Proc Natl Acad Sci U S A (1995) 2.61
The ubiquitin conjugation system is required for ligand-induced endocytosis and degradation of the growth hormone receptor. EMBO J (1996) 2.58
Immunochemical analysis of the turnover of ubiquitin-protein conjugates in intact cells. Relationship to the breakdown of abnormal proteins. J Biol Chem (1982) 2.56
Resolution of the ATP-dependent proteolytic system from reticulocytes: a component that interacts with ATP. Proc Natl Acad Sci U S A (1979) 2.37
A Chinese hamster cell cycle mutant arrested at G2 phase has a temperature-sensitive ubiquitin-activating enzyme, E1. J Biol Chem (1988) 2.33
A novel site for ubiquitination: the N-terminal residue, and not internal lysines of MyoD, is essential for conjugation and degradation of the protein. EMBO J (1998) 2.31
HLA-A11 epitope loss isolates of Epstein-Barr virus from a highly A11+ population. Science (1993) 2.28
Mutation of the E6-AP ubiquitin ligase reduces nuclear inclusion frequency while accelerating polyglutamine-induced pathology in SCA1 mice. Neuron (1999) 2.25
"Covalent affinity" purification of ubiquitin-activating enzyme. J Biol Chem (1982) 2.15
Ubiquitin-dependent degradation of certain protein substrates in vitro requires the molecular chaperone Hsc70. J Biol Chem (1997) 2.14
The asialoglycoprotein receptor internalizes and recycles independently of the transferrin and insulin receptors. Cell (1983) 2.10
The ubiquitin-mediated proteolytic pathway and mechanisms of energy-dependent intracellular protein degradation. J Cell Biochem (1984) 2.10
T cell responses and virus evolution: loss of HLA A11-restricted CTL epitopes in Epstein-Barr virus isolates from highly A11-positive populations by selective mutation of anchor residues. J Exp Med (1994) 2.04
The ubiquitin pathway for the degradation of intracellular proteins. Prog Nucleic Acid Res Mol Biol (1986) 1.98
A minimal glycine-alanine repeat prevents the interaction of ubiquitinated I kappaB alpha with the proteasome: a new mechanism for selective inhibition of proteolysis. Nat Med (1998) 1.96
Basal and human papillomavirus E6 oncoprotein-induced degradation of Myc proteins by the ubiquitin pathway. Proc Natl Acad Sci U S A (1998) 1.88
Modes of regulation of ubiquitin-mediated protein degradation. J Cell Physiol (2000) 1.82
Inhibition of NF-kappa-B cellular function via specific targeting of the I-kappa-B-ubiquitin ligase. EMBO J (1997) 1.78
The role of methylation in the phenotype-dependent modulation of Epstein-Barr nuclear antigen 2 and latent membrane protein genes in cells latently infected with Epstein-Barr virus. J Gen Virol (1989) 1.77
Itch: a HECT-type E3 ligase regulating immunity, skin and cancer. Cell Death Differ (2008) 1.77
Multiple HLA A11-restricted cytotoxic T-lymphocyte epitopes of different immunogenicities in the Epstein-Barr virus-encoded nuclear antigen 4. J Virol (1993) 1.77
Down-regulation of class I HLA antigens and of the Epstein-Barr virus-encoded latent membrane protein in Burkitt lymphoma lines. Proc Natl Acad Sci U S A (1987) 1.77
Reversion of tumorigenicity and decreased agarose clonability after EBV conversion of an IgH/myc translocation-carrying BL line. Int J Cancer (1989) 1.74
Protein synthesis elongation factor EF-1 alpha is essential for ubiquitin-dependent degradation of certain N alpha-acetylated proteins and may be substituted for by the bacterial elongation factor EF-Tu. Proc Natl Acad Sci U S A (1994) 1.72
Role of arginine-tRNA in protein degradation by the ubiquitin pathway. Nature (1987) 1.71
Degradation of the E7 human papillomavirus oncoprotein by the ubiquitin-proteasome system: targeting via ubiquitination of the N-terminal residue. Oncogene (2000) 1.67
How are substrates recognized by the ubiquitin-mediated proteolytic system? Trends Biochem Sci (1989) 1.66
Interleukin 10 pretreatment protects target cells from tumor- and allo-specific cytotoxic T cells and downregulates HLA class I expression. J Exp Med (1994) 1.66
SCF(beta)(-TrCP) ubiquitin ligase-mediated processing of NF-kappaB p105 requires phosphorylation of its C-terminus by IkappaB kinase. EMBO J (2000) 1.55
Patterns of Epstein-Barr virus infection in non-neoplastic lymphoid tissue. Blood (1992) 1.51
Characterization of the heat-stable polypeptide of the ATP-dependent proteolytic system from reticulocytes. J Biol Chem (1980) 1.51
Degradation of ornithine decarboxylase in reticulocyte lysate is ATP-dependent but ubiquitin-independent. J Biol Chem (1989) 1.50
Characterization of EBV-carrying B-cell populations in healthy seropositive individuals with regard to density, release of transforming virus and spontaneous outgrowth. Int J Cancer (1987) 1.48
Degradation of the proto-oncogene product c-Fos by the ubiquitin proteolytic system in vivo and in vitro: identification and characterization of the conjugating enzymes. Mol Cell Biol (1995) 1.48
Activation of the heat-stable polypeptide of the ATP-dependent proteolytic system. Proc Natl Acad Sci U S A (1981) 1.48
Complete switch from Mdm2 to human papillomavirus E6-mediated degradation of p53 in cervical cancer cells. Proc Natl Acad Sci U S A (2001) 1.47
Disappearance of the NK effect after explantation of lymphocytes and generation of similar nonspecific cytotoxicity correlated to the level of blastogenesis in activated cultures. J Immunol (1980) 1.47
Degradation of ornithine decarboxylase in mammalian cells is ATP dependent but ubiquitin independent. Eur J Biochem (1989) 1.45
Degradation of myogenic transcription factor MyoD by the ubiquitin pathway in vivo and in vitro: regulation by specific DNA binding. Mol Cell Biol (1998) 1.41
Degradation of the epstein-barr virus latent membrane protein 1 (LMP1) by the ubiquitin-proteasome pathway. Targeting via ubiquitination of the N-terminal residue. J Biol Chem (2000) 1.40
Identification of the ubiquitin carrier proteins, E2s, involved in signal-induced conjugation and subsequent degradation of IkappaBalpha. J Biol Chem (1999) 1.39
Ubiquitination of E3 ligases: self-regulation of the ubiquitin system via proteolytic and non-proteolytic mechanisms. Cell Death Differ (2011) 1.39
Differentiation-dependent sensitivity of human B-cell-derived lines to major histocompatibility complex-restricted T-cell cytotoxicity. Proc Natl Acad Sci U S A (1986) 1.38
Molecular cloning, sequence, and tissue distribution of the human ubiquitin-activating enzyme E1. Proc Natl Acad Sci U S A (1991) 1.38
Degradation of proteins with acetylated amino termini by the ubiquitin system. Science (1989) 1.37
Sorting and recycling of cell surface receptors and endocytosed ligands: the asialoglycoprotein and transferrin receptors. J Cell Biochem (1983) 1.37
Mammalian reticulocytes lose adhesion to fibronectin during maturation to erythrocytes. Proc Natl Acad Sci U S A (1985) 1.32
An HLA-A11-specific motif in nonamer peptides derived from viral and cellular proteins. Proc Natl Acad Sci U S A (1993) 1.30
Role of UEV-1, an inactive variant of the E2 ubiquitin-conjugating enzymes, in in vitro differentiation and cell cycle behavior of HT-29-M6 intestinal mucosecretory cells. Mol Cell Biol (1998) 1.30
Recognition of the Epstein-Barr virus-encoded nuclear antigens EBNA-4 and EBNA-6 by HLA-A11-restricted cytotoxic T lymphocytes: implications for down-regulation of HLA-A11 in Burkitt lymphoma. Proc Natl Acad Sci U S A (1992) 1.28
Intracellular transport of transferrin- and asialoorosomucoid-colloidal gold conjugates to lysosomes after receptor-mediated endocytosis. J Histochem Cytochem (1985) 1.27
Three Epstein-Barr virus latency proteins independently promote genomic instability by inducing DNA damage, inhibiting DNA repair and inactivating cell cycle checkpoints. Oncogene (2009) 1.27
Differential interaction of plakoglobin and beta-catenin with the ubiquitin-proteasome system. Oncogene (2000) 1.25
Regulation of the Drosophila ubiquitin ligase DIAP1 is mediated via several distinct ubiquitin system pathways. Cell Death Differ (2007) 1.23
Transfer RNA is an essential component of the ubiquitin- and ATP-dependent proteolytic system. Proc Natl Acad Sci U S A (1985) 1.23
Structural motifs involved in ubiquitin-mediated processing of the NF-kappaB precursor p105: roles of the glycine-rich region and a downstream ubiquitination domain. Mol Cell Biol (1999) 1.22
Purification and characterization of a novel species of ubiquitin-carrier protein, E2, that is involved in degradation of non-"N-end rule" protein substrates. J Biol Chem (1994) 1.21
The Epstein-Barr virus latent membrane protein-1 (LMP1) induces interleukin-10 production in Burkitt lymphoma lines. Int J Cancer (1994) 1.20
c-Abl regulates p53 levels under normal and stress conditions by preventing its nuclear export and ubiquitination. Mol Cell Biol (2001) 1.19
Epstein-Barr virus promotes genomic instability in Burkitt's lymphoma. Oncogene (2007) 1.16
Post-translational addition of an arginine moiety to acidic NH2 termini of proteins is required for their recognition by ubiquitin-protein ligase. J Biol Chem (1990) 1.15
Identification of the active amino acid residue of the polypeptide of ATP-dependent protein breakdown. J Biol Chem (1981) 1.14
The nuclear ubiquitin-proteasome system degrades MyoD. J Biol Chem (2001) 1.13
Transfer RNA is required for conjugation of ubiquitin to selective substrates of the ubiquitin- and ATP-dependent proteolytic system. J Biol Chem (1986) 1.13
c-myc overexpression activates alternative pathways for intracellular proteolysis in lymphoma cells. Nat Cell Biol (2001) 1.13
Large granular lymphocytes inhibit the in vitro growth of autologous Epstein-Barr virus-infected B cells. Cell Immunol (1983) 1.11
Immunoelectron microscopic localization of ubiquitin in hepatoma cells. EMBO J (1988) 1.09
Degradation of ornithine decarboxylase by the mammalian and yeast 26S proteasome complexes requires all the components of the protease. Eur J Biochem (1995) 1.09
Epitope-dependent selection of highly restricted or diverse T cell receptor repertoires in response to persistent infection by Epstein-Barr virus. J Exp Med (1997) 1.09
Effect of interferon-alpha 1 from E. coli on some cell functions. Science (1980) 1.08
The ubiquitin-activating enzyme, E1, is required for stress-induced lysosomal degradation of cellular proteins. J Biol Chem (1991) 1.07
Antibody-induced receptor loss. Different fates for asialoglycoproteins and the asialoglycoprotein receptor in HepG2 cells. J Biol Chem (1986) 1.06
Virologic, immunologic, and clinical observations on a patient during the incubation, acute, and convalescent phases of infectious mononucleosis. Clin Immunol Immunopathol (1984) 1.05
Ubiquitin-activating enzyme, E1, is associated with maturation of autophagic vacuoles. J Cell Biol (1992) 1.04
On the involvement of calpains in the degradation of the tumor suppressor protein p53. FEBS Lett (1997) 1.03
Down-regulation of the EBV-encoded membrane protein (LMP) in Burkitt lymphomas. Int J Cancer (1987) 1.03
The herpes simplex virus-1 Us3 protein kinase blocks CD8T cell lysis by preventing the cleavage of Bid by granzyme B. Cell Death Differ (2003) 1.03
The eye lens has an active ubiquitin-protein conjugation system. J Biol Chem (1986) 1.02